Galenica Ag · SIX:GALE
Galenica — H1 2026 Earnings Presentation
29 slides from Galenica's earnings presentation, Aug 6, 2026
Slide 1: Galenica maintains its track record of consistent growth
Galenica maintains its track record of consistent growth Half Year Results 2026 August 6, 2026
Slide 2: Highlights and Strategic Update
1 Highlights and Strategic Update
Slide 3: Continuous growth, strong strategy execution
Continuous growth, strong strategy execution Strong sales growth EBIT on track CHF 2.14 billion CHF 117.7 million
Slide 4: Our focus in the first half of 2026
Our focus in the first half of 2026 Market share Streamlined home Integration of gains in pharmacy care business Labor Team business thanks to keeps growing on track omni-channel Consultation plus established in all Galenica pharmacies
Slide 5: Consultation plus established in all Galenica pharmacies
Consultation plus established in all Galenica pharmacies 193,000 Health consultations 25,000 vaccinations 1,000,000 policy holders eligible for Arzt cost coverage
Slide 6: Omni-channel strategy as basis for future growth in pharmacy business
Omni-channel strategy as basis for future growth in pharmacy business Prescription manager user Click-and-Collect OTC growth liberalisation as a chance Customer retention Arzt Efficiency gains for pharmacies
Slide 7: Our focus in the first half of 2026
Our focus in the first half of 2026 Market share Streamlined home Integration of gains in pharmacy care business Labor Team business thanks to keeps growing on track omni-channel Consultation plus established in all Galenica pharmacies
Slide 8: Our focus in the first half of 2026
Our focus in the first half of 2026 Streamlined home Integration of care business Labor Team keeps growing on track Streamlined home care business keeps growing
Slide 9: Streamlined home care business keeps growing
Streamlined home care business keeps growing Portfolio Integration of Automation of optimization of Bichsel Home Care blister packaging Bichsel and focus on and Lifestage business at Medifilm home care business Solutions
Slide 10: Our focus in the first half of 2026
Our focus in the first half of 2026 Streamlined home Integration of care business Labor Team keeps growing on track Streamlined home care business keeps growing Integration of Labor Team on track
Slide 11: Our focus in the first half of 2026
Our focus in the first half of 2026 Integration of Labor Team on track Integration of Labor Team on track
Slide 12: Integration of Labor Team on track
Integration of Labor Team on track Focus on synergies and All large-scale tests fully combined product offering automated for physicians Clinical chemistry Anatomical pathology Haematology Immunology Microbiology New Core Lab
Slide 13: Transformation continues in the second half of 2026
Transformation continues in the second half of 2026 Expected Integrating our efficiency gains network for from wholesale more synergies modernisation and improved product offering
Slide 14: Financial Results Half Year 2026
2 Financial Results Half Year 2026
Slide 15: Swiss pharmaceutical market June 2026
Swiss pharmaceutical market June 2026 Hospitals CHF 962.4 million (+0.2%) Total market growth 7.7 million packs (+1.2%) CHF 4,074.7 million (+3.7%) 99.1 million packs (-0.6%) 23.6% Drugstores 0.7% 43.6% Local Pharmacies CHF 29.0 million (-2.9%) CHF 1,777.6 million (+5.4%) 2.7 million packs (-4.3%) 6
Slide 16: Local pharmacy market June 2026
Local pharmacy market June 2026 Total market growth CHF 3’342 million (+4.2%) Other List E / free assortment +0.5% Prescription medicine List A & B Non-prescription medicine +6.9% List D -0.3% Source: IQVIA PharmaTrend for pharmacies and drugstores in Switzerland, streetprices © IQVIA – Consumer Hea
Slide 17: Galenica Group: Strong sales growth supported by acquisition of Labor Team
Galenica Group Strong sales growth supported by acquisition of Labor Team Net sales (in million CHF) +7.1% 2,136 +4.2% 1,995 1,618 1,685 +11.5% 967 H1 2025 867 H1 2026 Galenica Group Products & Care Logistics & IT Growth w/o Labor Team +4.0% +4.3% +4.2%
Slide 18: Pharmacies Omni-Channel: Growth driven by prescription medicines and acquisitions
Pharmacies Omni-Channel Growth driven by prescription medicines and acquisitions Net sales (in million CHF) Expansion impact1 of +1.9% due to 1,473 acquisition of majority stake in puravita, portfolio of local pharmacies expanded by 3 locations +6.2% 713 757 Generics substitution rate remains with 7
Slide 19: Products & Brands: Seasonal effects burden sales development
Products & Brands Seasonal effects burden sales development Net sales (in million CHF) 194 -9.8% 36 International 101 Swiss market: 91 Swiss market − Growth of CH market sales1 -2.6% 21 15 -27.8% 158 − Market share1 of 10.5% 80 76 -5.1% 2025 H1 2025 H1 2026 1) Product sales to end customers of Verfo
Slide 20: Services & Production: Strong sales growth in homecare business
Services & Production Strong sales growth in homecare business Net sales (in million CHF) 120 +9.4% Consistent, strong growth with services for homecare 63 58 organizations and nursing homes 2025 H1 2025 H1 2026
Slide 21: Wholesale: Further market share gains in pharmacies segments
Wholesale Further market share gains in pharmacies segments Net sales (in million CHF) 3,255 934 Physicians +4.3% Pharmacies 1,580 1,647 Others 461 465 +1.0% 2,136 1’027 1’092 +6.3% 185 92 90 -2.0% 2025 H1 2025 H1 2026
Slide 22: Strong EBIT growth excluding prior-year one-off effects
Strong EBIT growth excluding prior-year one-off effects EBIT adjusted1) (in million CHF) ROS (in %) 117.7 +12.6% 109.9 104.5 25.3 +2.0% 30.2 -5.4 1.5% 1.9% 24.8 1.5% Logistics & IT Products & Care 93.3 +15.2% 81.0 81.0 9.6% 9.3% 9.3% H1 2025 3 one-off 2 H1 2025 H1 2026 items w/o one-off 1 without ef
Slide 23: Cash Flow Statement: Cashflow lowered due to seasonal effects
Cash Flow Statement Cashflow lowered due to seasonal effects in million CHF H1 2025 H1 2026 Change Cash flow from operating activities before working 125.8 126.7 +0.8 capital changes adjusted1 Working capital changes -43.5 -93.8 1 Cash flow from operating activities adjusted 82.4 32.9 -49.5 Investme
Slide 24: Balance sheet: Debt coverage shift driven by seasonal WC build
Balance sheet Debt coverage shift driven by seasonal WC build in million CHF 1,509 1,465 1,443 Equity adjusted1 837 675 Net debt adjusted1 533 2025 H1 2025 H1 2026 Debt coverage 2.3x 1.9x 2.7x adjusted2 1 Detail of the adjustments in the Half year report 2026, see chapter “Alternative performance me
Slide 25: Regulatory environment: Lab price cuts and OTC liberalisation one year earlier
Regulatory environment Lab price cuts and OTC liberalisation one year earlier Topic/Initiative Changes since FY 2025 presentation OTC products:1 − Implementation earliest in 2029 instead of 2030 online trade As part of the FOPH's 2026 cost-containment package, effective H2 2026: TransAL2 and TarDoc
Slide 26: Guidance 2026 confirmed
Guidance 2026 confirmed Galenica Group EBIT adjusted1,2 Dividend net sales for 2026 at least at +5% +6% prior-year to +7% to +8% level 1 without effects of IAS 19, IFRS 16, IFRS3 and one-off effects, see chapter “Alternative performance measures” of the Half year report 2026 2 corresponds +9% to +11
Slide 27: Well positioned for the second half of 2026
Well positioned for the second half of 2026
Slide 28: Galenica
Galenica @i
Slide 29: Disclaimer
Disclaimer Disclaimer Galenica Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company’s or, as appropriate, the Company’s directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a n